Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Determination of the Effect of a SERCA Agonist on the Reduction of ER Stress from US Patent US11890279: "Quinolines that modulate SERCA and their use for treating disease"
Assay data:11 Tested
SummaryRelated BioAssays by Target
Cross screening panel
Assay data:1 Tested
Safety47 Scan (DiscoverX - Eurofins)
Adenosine A2A Eurofins Panlabs panel
A2A/H Eurofins SafetyScreen44 (BI)
Binding affinity towards human ADORA2A in an in vitro assay with cellular components measured by scintillation proximity assay
Assay data:16 Active, 3 Activity ≤ 1 µM, 1202 Tested
Inhibition of adenosine A2A receptor (unknown origin) upto 10000 nM
Binding affinity to human adenosine A2A receptor assessed as inhibition constant
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Displacement of [3H]-CGS 21680 from human recombinant adenosine A2A receptor at 10 uM after 120 mins by scintillation counting analysis relative to control
Assay data:3 Tested
Binding affinity to A2A receptor (unknown origin)
Inhibition of Adenosine A2A receptor (unknown origin) at 10 uM
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on